The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2
Open Access
- 1 June 2000
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 11 (6) , 647-663
- https://doi.org/10.1023/a:1008390429428
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Controlling Cell DeathScience, 1997
- Apoptosis Meets Signal Transduction: Elimination of a BAD InfluenceCell, 1996
- Possible mechanisms in the emergence of tamoxifen-resistant breast cancerAnti-Cancer Drugs, 1995
- The hunt for Ras targetsNature, 1994
- The regulation of p53 function: Steiner award lectureInternational Journal of Cancer, 1994
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 1992